Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model

Acta Ophthalmologica

Volumn 92, Issue 4, 2014, Pages

  Januschowski, Kai ^a   Schnichels, Sven ^a   Hagemann, Ulrike ^a   Koch, Vanessa ^a   Hofmann, Johanna ^a   Spitzer, Martin S ^a   Bartz Schmidt, Karl Ulrich ^a   Szurman, Peter ^a   Lüke, Matthias ^b   Aisenbrey, Sabine ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

aflibercept; electroretinogram; intraocular toxicity; retinal toxicity; superfused retina

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

A WAVE; AMPLITUDE MODULATION; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B WAVE; BIOCOMPATIBILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; ELECTRORETINOGRAM; EYE TOXICITY; ISOLATED RETINA; NICK END LABELING; NONHUMAN; ORGAN CULTURE; PHOTORECEPTOR POTENTIAL; PRIORITY JOURNAL; RETINA BIPOLAR GANGLION CELL; RETINA GANGLION CELL; RETINA INJURY; RETINA ROD OUTER SEGMENT; TOXICITY TESTING; ANIMAL; BIOLOGICAL MODEL; BOVINAE; DRUG EFFECTS; ELECTRORETINOGRAPHY; ORGAN CULTURE TECHNIQUE; RETINA; TOXICITY;

ANIMALS; APOPTOSIS; CATTLE; ELECTRORETINOGRAPHY; IN SITU NICK-END LABELING; MODELS, BIOLOGICAL; ORGAN CULTURE TECHNIQUES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA;

EID: 84901332836     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12300     Document Type: Article

References (26)

1. Abraham P, Yue H, &, Wilson L, (2010): Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150: 315-324.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, & ANCHOR Study Group (2009): Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
3. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, &, Jaffe GJ, (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
4. Do DV, Nguyen QD, Shah SM, et al. (2009): An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 93: 144-149.
5. Folk JC, &, Stone EM, (2010): Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 363: 1648-1655.
6. Fung AE, Lalwani GA, Rosenfeld PJ, et al. (2007): An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, & VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
8. Heier JS, Brown DM, Chong V, et al. (2012): Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119: 2537-2548.
9. Holash J, Davis S, Papadopoulos N, et al. (2002): VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398.
10. Januschowski K, Mueller S, Spitzer MS, Schramm C, Doycheva D, Bartz-Schmidt KU, &, Szurman P, (2012): Evaluating retinal toxicity of a new heavy intraocular dye, using a model of perfused and isolated retinal cultures of bovine and human origin. Graefes Arch Clin Exp Ophthalmol 250: 1013-1022.
11. Kvanta A, (2006): Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 84: 282-288.
12. Lüke M, Weiergräber M, Brand C, Siapich SA, Banat M, Hescheler J, Lüke C, &, Schneider T, (2005): The isolated perfused bovine retina-a sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 16: 27-36.
13. Lüke M, Januschowski K, Warga M, et al. (2007): The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 91: 1077-1082.
14. Lüke M, Januschowski K, Lüke J, et al. (2009): The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina. Br J Ophthalmol 93: 1396-1400.
15. Lüke M, Januschowski K, Tura A, et al. (2010): Effects of pegaptanib sodium on retinal function in isolated perfused vertebrate retina. Curr Eye Res 35: 248-254.
16. Moshfeghi AA, &, Puliafito CA, (2005): Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 14: 671-682.
17. Nguyen QD, (2008): CLEAR-IT 2. Summary of One-Year. Key Results, in Retina Society Meeting. September 28,: Scottsdale, AZ.
18. Nguyen Q, (for the CLEAR-IT 1 investigators) 2007: A randomized comparison of the safety, tolerability, and bioactivity study two dose levels of intravitreal VEGF trap in patients with neovascular age-related macular degeneration, in Retina Society Annual Scientific Meeting Sep 27-30th, Boston, MA.
19. Perlman I, (2009): Testing retinal toxicity of drugs in animal models using electrophysiological and morphological techniques. Doc Ophthalmol 118: 3-28.
20. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, &, Shams N, (2008): Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
21. Richter SH, Garner JP, &, Wurbel H, (2009): Environmental standardization: cure or cause of poor reproducibility in animal experiments? Nat Methods 6: 257-261.
22. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, & MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
23. Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, &, Aisenbrey S, (2013): Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol 97: 917-923.
24. Spitzer MS, Wallenfels-Thilo B, et al. (2006): Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90: 1316-1321.
25. Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, &, Szurman P, (2007): Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 245: 1837-1842.
26. Stewart MW, &, Rosenfeld PJ, (2008): Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92: 667-668.